Detection of Low-Risk and High-Risk Oncogenic Human Papillomavirus in Archived Tissues from ENT Tumors in Burkina Faso

Human papillomavirus (HPV) is classified into high-risk HPV (HR-HPV) and HPV (LR-HPV) according to their oncogenic potential. These viruses can be found in the cervix, vagina, vulva, anus and in the ENT sphere. HPV ENT infections can lead to benign or malignant tumors in which we could find both LR-HPV and HR-HPV genotypes


Introduction
Human papillomavirus (HPV) is a double-stranded circular DNA virus belonging to the papillomavirus family.Infection by HPV is one of the most common infections in the world [1].These viruses are classified into high-risk HPV (HR-HPV) and low-risk HPV (LR-HPV) according to their oncogenic potential.The role of HR-HPV in the development of cervical cancer has been well demonstrated for many years [2] [3].HPV infections are found in the cervix as well as the vulva, anus, vagina and ENT sphere [4] [5].ENT infections are quite common and can lead to benign tumors but also to cancers.Papillomatosis is a benign tumor characterized by the proliferation of epithelial cells in clusters.This proliferation most often occurs in the larynx (laryngeal papillomatosis) and the nasal cavity (inverted papilloma, exophytic and oncocytic papillomas).About 75% to 85% of these benign lesions are found LR-HPV genotypes 6 and 114.Concerning malignant tumors such as ENT cancers, they are unfortunately discovered at late stages leaving little time for adequate care.The involvement of HR-HPV in ENT cancers has been recognized [6] [7].It seems that the management of these HPV positive cancers is less complex, and they have a better prognosis compared to negative HPV ENT cancers 6. Depending on the type of tumor, the treatment calls for therapeutic modalities, combining lymph node tumor surgery, radiotherapy, and chemotherapy [8].The identification of different HPV genotypes in ENT tumors could improve the prognosis and influence the therapeutic modalities.The 2008 National Comprehensive Cancer Network (NCCN) guidelines suggested HPV testing for oropharyngeal tumors [9].Some countries like Burkina Faso in West Africa are not there for the moment.In this country, studies on archived biopsies tissues from ENT tumor reported in the registers of anatomy and cyto-pathology centers are helpful.A retrospection of these cases could guide on the types of HPV that are involved in ENT tumors in the country.So, this study focused on the diversity of HPV genotypes found in archived tissues from ENT benign and malignant tumors in the capital city, Ouagadougou.We hypothesized that both low-risk and high-risk HPV are found in ENT tumors regardless of type of tumors (benign or malignant).To test this hypothesis, HPV was investigated in the archived tissues and the frequencies of HR-HPV and LR-HPV were determined.

Study Site, Type, and Population
We conducted a descriptive cross-sectional study with a collection of archived tissues over a 10-year period between 2007-2017 in four anatomy and cy-A.Kandé

Sampling and Data Collection
This study was based on existing data from hospital registers recorded over a The selected numbers from registers were used to search for the corresponding blocks which were cut by microtome, to obtain sections of thickness ≤ 20 µm for each sample.The samples were introduced on nuclease-free Eppendorf tubes and transported to the Molecular Biology and Genetics Laboratory (CERBA/ LABIOGENE), Joseph KI-ZERBO University for molecular analysis.

Dewaxing of the Tissues
All the tissues were first treated with 10% PBS.Then 1 mL of xylene was added to the sample, vortexed and incubated at 50˚C for 10 minutes and centrifuged at 14,000 RPM for 2 minutes.The supernatant was removed, and the xylem step was repeated a second time.Finally, 1 ml of absolute ethanol was added to the sample, which we then vortexed and centrifuged at 14,000 RPM for 2 minutes.
The supernatant was discarded, and the ethanol step was repeated a second time.

HPV DNA Extraction
The NORGEN FFPE DNA Purification kit was used for HPV DNA extraction according to the manufacturer's protocol.We proceeded with the cell lysis step, followed by incubation at 50˚C for 1 hour and 90˚C for 1 hour to release the genetic material.The DNA was precipitated with absolute ethanol, washing of the columns and elution of the DNA were performed.The DNA obtained was stored at −20˚C until amplification by PCR.

Real-Time Multiplex PCR
Extracted DNA was amplified by multiplex RT-PCR with the SaCycler-96 Real Time PCR v.7.3 (Sacace Biotechnologies, Italy) using two kits and following the protocol described by the manufacturer.Journal of Biosciences and Medicines The detection of low-risk HPV was carried out using the "HPV low Risk

Statistical Analysis
Statistical analyses were performed using IBM SPSS statistics 20 software and the chi-square test was used to compare results.The results were considered significant for a p-value of less than 5%.

Ethical Considerations
The study was approved by the Health Research Ethics Committee (CERS) of Burkina Faso: "Deliberation n˚2022-03-066 of March 02, 2022".The confidentiality of the data collected has been respected.

Characteristics of the Included Samples
This study included one hundred and twenty (120) ENT tumor tissues with histological diagnosis revealing 94 cases of malignant tumors and 26 cases of benign tumors.Among tissues from cancers, the most frequent histological type reported in registries was carcinoma with 77.65% (73/94), followed by lymphoma 11.70% (11/94), sarcoma 4.25% (4/94), melanoma 3.20% (3/94) and cylindroma 3.20% (3/94).Tissue blocks were collected from 70 male and 50 female patients with a sex ratio of 1.4; patients' age ranged from 2 to 69 years.For female, they were 74% (37/50) cases of malignant tumors compared to 81.43% (57/70) cases among male (Figure 1).The difference between type of tumors in male and female was not statistically different (p value = 0.33).

Prevalence of HPV Infection
A valid PCR result was obtained with all 120 archived paraffin-fixed tissue blocks included in this study.The prevalence of HPV was respectively 57.7% (15/26) and 43.61% (41/94) in benign tumors and malignant tumors (Table 1).
The combined prevalence of HPV infection regardless of the tumor type was 46.67% (56/120).Of the 16 HPV (14 HR-HPV and 2 LR-HPV) genotypes tested, Figure 1.Distribution of samples according to gender and type of tumors.2).

Distribution of HPV Genotypes in Co-Infected Samples
Among the HPV positive samples, there were 12 cases of co-infections 21.43% (12/56) regardless of HPV genotypes with 10 cases of double infection and 2 cases of triple infection.HPV 33 was the most common genotype in the different co-infections.There were 2 cases of co-infection between HR-HPV genotypes 16.6% (2/12), 5 cases of co-infection between LR-HPV genotypes 41.7% (5/12) and 5 cases of co-infection between LR-HPV and HR-HPV genotypes (Table 2).

Distribution of HR-HPV and LR-HPV in Tumors
Among the 56 samples positive to HPV, 15 samples were from benign tumors while the remaining 41 were from malignant tumors.Table 3 shows that the HR-HPV were found in 13.33% (2/15) of benign tumors versus 48.8% (20/41) of malignant tumors (p = 0.08).As for LR-HPV, they were present in 86.7% (13/15) of benign tumors against 51.2% (21/41) of malignant tumors with a significant p value (p = 0.02).

Discussion
This study focused on ENT tumors tissues archived in anatomy and cyto-pathology Table 2. Distribution of HPV genotypes in co-infected samples.
In the present study, the frequency of malignant tumors was higher in male (81.43%) than in female (74%).Our results were similar to those reported in the literature about the male predominance in oral cavity cancers [11].According to the authors of the study carried out in Ouagadougou, their results could be explained by poor oral hygiene more common in women than in men in Burkina Faso [12].For this study, we only had the information found in the registers, which did not allow us to analyze many socio-demographic characteristics of the patients.However, the frequency of malignant tumors was not different between women and men.This study reports a general prevalence of 46.67% (56/120) in ENT tumors.This prevalence is close to that of 46.5% found in oropharyngeal carcinomas in France [13] and 45.9% found in Japan [14].However, it remains lower than the 71% obtained in the United States [15] and higher than several studies in Africa including the one that reported a prevalence of 3.4% in Senegal [16] and 19.23% in Ghana [17].Among all HPV genotypes tested in the present study, 8/14 HR-HPV and 2/2 LR-HPV were found.The 4 most frequent genotypes were HPV 11, HPV 6, HPV 56 and HPV 33.The predominance of LR-HPV in the samples included in the present study is not really surprising.Indeed, the LR-HPV 6 and 11 are recognized as the genotypes found in laryngeal papillomatosis [18] corresponding to the group "benign tumors" in this study.HPV types 16 and 18 are HPV 16 and 18 are globally responsible for 85% of cancer of the head and neck [19].For the present study, HPV 16 and HPV 18 were classified as 5th most frequent with the same frequency of 2.6%.This distribution follows the same pattern as many HPV studies on cervical samples in Burkina [5] [20] [21] [22] which showed that HPV 16 and 18 were not the most frequent as elsewhere in the world.
In this study, multiple infections accounted for 21.43% (12/56) among the HPV positive samples.In general, co-infections between the different types of HPV are frequent and an HPV infection can be associated with HR-HPV and LR-HPV.Co-infections between HR-HPV were less frequently accounted for (16.6%) compared to LR-HPV co-infections (41.7%) and LR-HPV/HR-HPV co-infections (41.7%).
It is known that the pathologies associated with HPV vary depending on the genotype involved.LR-HPV is not associated with the development of cancer, but malignant transformation can occur if the pathology is also associated with HR-HPV [23].Given that HPV transmission can be oro-sexual [24], this could explain the presence of high-risk genotypes in the ENT sphere.For the present study, the HR-HPV was found in both benign and malignant tumors with respectively frequency of 13.33% (2/15) and 48.8% (20/41).In general, benign tumors (in this case laryngeal papillomatosis) do not become cancerous [25]  Depending on the type of lesion and the location, different types of treatment are recommended, including surgical excision.However, no therapeutic method allows for the eradication of the virus.This is explained by the fact that the virus can persist lesions.It is therefore crucial to focus on hygiene and vaccination in the fight against HPV induced ENT tumors.
A nonavalent vaccine is available and directed against HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58.It covers 6 genotypes of HR-HPV and the two genotypes of LR-HPV encountered in our study.In Burkina Faso, the use of the nonavalent vaccine could be expected to prevent certain HPV induced ENT tumors.
Despite the results obtained, this study has a number of limitations.One of the main limitations of this study was the lack of information on the habits and behaviors of the patients whose tissues were included.This did not allow for a discussion of the socio-demographic characteristics.In addition, the sample size was small due to the lack of registration of tumor cases in the country's health facilities.

Conclusion
Both low-risk and high-risk HPV are found in archived tissues from ENT tumors in Ouagadougou, Burkina Faso.The HPV prevalence obtained were relatively high reporting the involvement of these viruses in ENT tumors.These kinds of data about the repartition of HPV types may be useful to tailor vaccination and intervention strategies.

Figure 2 .
Figure 2. Prevalence of HPV genotypes in samples.
but DOI: 10.4236/jbm.2023.119015178 Journal of Biosciences and Medicines the presence of HR-HPV should lead to more monitoring of affected patients.
et al.
Typing Real TM V11-100FRT (6 and 11)" PCR kit from SACACE biotechnologies ® .This kit permits the detection of two low risk HPV genotypes (HPV 6 and HPV 11).The detection of high-risk oncogenic HPV in the DNA extracts of this

Table 1 .
Presence of HPV according to the type of tumor.

Table 3 .
Repartition of LR-HPV and HR-HPV according to type of tumor.
centers in Ouagadougou, Burkina Faso over a period of 10 years.In this country as elsewhere, the ENT pathologies are generally infections, trauma, tumors, and FREQUENCY % HPV GENOTYPES Journal of Biosciences and Medicines